Molecular profile
- Sequence
- GLP-1/Glucagon receptor dual agonist
- Molecular Formula
- C192H289N47O61
- Molecular Weight
- 4290.76 g/mol
- Synonyms
- BI 456906
Peptide research profile
Survodutide
Survodutide (BI 456906) is a dual glucagon/GLP-1 receptor agonist being developed by Boehringer Ingelheim. It is designed for weight management and the treatment of metabolic disorders such as obesity and type 2 diabetes. Clinical trials have shown that Survodutide can significantly reduce body weight and improve metabolic health by promoting satiety and enhancing energy expenditure.
Dosing literacy
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context—not a protocol or recommendation.
Recorded amount context
Mass amounts available for comparison
- Lower range1.2 mcgWeeks 3–4
Recorded example with no verified study backing; shown for amount literacy only.
- Low-mid range4.8 mcgWeeks 11–12
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range1.8 mgWeeks 5–6
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Schedule literacy
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Research best practices
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Mechanism map
How Survodutide is being studied to work
This process map organizes available educational context. Individual claims remain subject to source-level verification.
- 01
Process stage
Mechanisms of Action
Research indicates that Survodutide works by binding to specific receptors in the brain and other tissues, which are involved in regulating hunger and energy expenditure. By activating these receptors, Survodutide helps reduce food intake, increase feelings of fullness, and boost energy expenditure,…
Research orientation
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 01
Mechanisms of Action
Research indicates that Survodutide works by binding to specific receptors in the brain and other tissues, which are involved in regulating hunger and energy expenditure.…
- 02
Therapeutic Potential
The therapeutic potential of Survodutide lies in its ability to modulate key metabolic pathways. By mimicking the action of natural hormones, Survodutide can regulate appetite, enhance satiety, and promote weight loss.…
- 03
Research on Survodutide
Preclinical Studies Preclinical studies on Survodutide have provided promising insights into its potential benefits. In various animal models, Survodutide has been shown to significantly reduce body weight, regulate…
- 04
Clinical Trials
Survodutide is currently undergoing extensive clinical trials to assess its safety and efficacy in humans. Preliminary results from these trials have been encouraging, with participants experiencing significant weight…
- 05
Advancements in Metabolic Health
The future of Survodutide in the field of metabolic health looks promising. As ongoing research continues to validate its effectiveness and safety, Survodutide is poised to become a key player in the management of…
- 06
Innovation in Peptide-Based Therapies
The development of Survodutide represents a significant advancement in peptide-based therapies. Its unique mechanism of action and therapeutic benefits highlight the immense potential of peptides in addressing complex…
Evidence map
What is known—and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Source review pending
Mechanisms of Action
Research indicates that Survodutide works by binding to specific receptors in the brain and other tissues, which are involved in regulating hunger and energy expenditure.…
- Source review pending
Therapeutic Potential
The therapeutic potential of Survodutide lies in its ability to modulate key metabolic pathways. By mimicking the action of natural hormones, Survodutide can regulate appetite, enhance satiety, and promote weight loss.…
- Source review pending
Research on Survodutide
Preclinical Studies Preclinical studies on Survodutide have provided promising insights into its potential benefits. In various animal models, Survodutide has been shown to significantly reduce body weight, regulate appetite, and improve metabolic health.…
Recorded protocol library
Amounts recorded for Survodutide
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 01
Weeks 3–4
1.2 mcg
Sign in for schedule, duration and source context.
- 02
Weeks 11–12
4.8 mcg
Sign in for schedule, duration and source context.
- 03
Weeks 5–6
1.8 mg
Sign in for schedule, duration and source context.
Technical reference
Identity, limitations and unknowns
Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Source review
1 links awaiting verification
- Source link · pmc.ncbi.nlm.nih.govVerification pending · Source review pending